8TJF

monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-CL interface

External Resource: Annotation

SAbDab Antibody Annotation
Thera-SAbDab Antibody Annotation

SAbDab Antibody Annotation SAbDab Database Homepage

Chain	Chain Class	Chain Subclass	Chain Type	Antigen Name(s)	Provenance Source
A [auth L], C [auth A]	Light Chain	IGKV1	Kappa	-	SAbDab (2024-09-27)
B [auth H], D [auth B]	Heavy Chain	IGHV3	-	-	SAbDab (2024-09-27)

Thera-SAbDab Antibody Annotation Thera-SAbDab Database Homepage

Chain	Name	Target	Provenance Source
A [auth L], C [auth A]	Anvatabart	ERBB2/CD340/HER2, CD3E, SIRPA	Therapeutic SAbDab (2024-09-27)
B [auth H], D [auth B]	Timigutuzumab	ERBB2/CD340/HER2, CD3E, SIRPA	Therapeutic SAbDab (2024-09-27)

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.